This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 23 May 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 15 November 2017, the Council decided that furanylfentanyl should be subject to control measures across the Member States. Furanylfentanyl is known from the scientific literature. Fentanyl is a fast but short-acting synthetic opioid that has been widely used in clinical practice.

Table of contents:
• EMCDDA actions on monitoring and responding to new drugs
• EMCDDA–Europol Joint Report on furanylfentanyl: a summary
• Risk Assessment Report of a new psychoactive substance: furanylfentanyl
• Annex 1: Technical report on furanylfentanyl
• Council Decision on subjecting furanylfentanyl to control measures
• Participants of the risk assessment meeting